Background: Clozapine, the classic atypical neuroleptic, exerts therap
eutic actions in schizophrenic patients unresponsive to most neurolept
ics. Clozapine interacts with numerous neurotransmitter receptors, and
selective actions at novel subtypes of dopamine and serotonin recepto
rs have been proposed to explain clozapine's unique psychotropic effec
ts. To identify sites with which clozapine preferentially interacts in
a therapeutic setting, we have characterized dozapine binding to brai
n membranes. Materials and Methods: [H-3]Clozapine binding was examine
d in rat brain membranes as well as cloned-expressed 5-HT6 serotonin r
eceptors. Results: [H-3]Clozapine binds with low nanomolar affinity to
two distinct sires. One reflects muscarinic receptors consistent with
the drug's anticholinergic actions. The drug competition profile of t
he second site most closely resembles 5HT(6) serotonin receptors, thou
gh serotonin itself displays low affinity. [H-3]Clozapine binding leve
ls are similar in all brain regions examined with no concentration in
the corpus striatum. Conclusions: Besides muscarinic receptors, clozap
ine primarily labels sites with properties resembling 5HT(6) serotonin
receptors. If this is also the site with which clozapine principally
interacts in intact human brain, it may account for the unique benefic
ial actions of clozapine and other atypical neuroleptics, and provide
a molecular target for developing new, safer, and more effective agent
s.